Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

Conditions

• Lymphoproliferative Disorder

Eligibility Criteria

Sex

ALL

Age

N/A - 30 Years

Healthy Volunteers

Not accepted

Interventions

• rituximab — BIOLOGICAL
  Cycles 1 and 2 only: Given IV Incremental: First dosage: \< 21 years of age: 0.5mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 50 mg/hr for the 1st hour. Subsequent dosages: \< 21 years of age: 1.0mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 100 mg/hr for the 1st hour. Days 1, 8 and 15.
• cyclophosphamide — DRUG
  Given IV over 30-60 minutes Dose 600 mg/m2 in 50-250 mL of normal saline (NS) or Dextrose-Water 5%(D5W) (at a maximum concentration of 20 mg/ml) over 30-60 minutes on day 1 of each cycle
• methylprednisolone — DRUG
  Methylprednisolone 0.8 mg/kg IV over 12 hours on days 1,2,3,4 and 5 of each cycle.
• prednisone — DRUG
  Dosage 1 mg/kg orally every 12 hours on days 1,2,3,4 and 5 of each cycle. Oral prednisone may be rounded up to the nearest 2.5 mg as necessary for tablet size

Study Details

RATIONALE: Drugs used in chemotherapy such as cyclophosphamide, prednisone, and methylprednisolone use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining cyclophosphamide and either prednisone or methylprednisolone with rituximab may be effective in treating lymphoproliferative disease following organ transplantation. PURPOSE: Phase II trial to study the effectiveness of combining cyclophosphamide and either prednisone or methylprednisolone with rituximab in treating patients who have Epstein-Barr virus-positive lymphoproliferative disease following organ transplantation.

Key Dates

Start date

Apr 30, 2004

Status verified

Sep 2016

Primary completion

Oct 1, 2009

Completion

Dec 31, 2013

Study Design

Enrollment

55 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Cyclophosphamide, prednisone, rituximab
  Patients receive cyclophosphamide IV over 30-60 minutes on day 1 and oral prednisone or methylprednisolone IV twice daily on days 1-5. During courses 1 and 2 only, patients also receive rituximab IV over 2-5 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression, a new primary or secondary malignancy, or unrelated disease

Primary Outcome Measure

Event-free Survival [ Time Frame: 2 years ]

Locations (66)

Find similar trials in Birmingham, AL

Related Studies

• 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
  Recruiting · Barbara Ann Karmanos Cancer Institute · Detroit, Michigan
• Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
  Recruiting · UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina
• Registry of Older Patients With Cancer
  Recruiting · UNC Lineberger Comprehensive Cancer Center · Boone, North Carolina
• Project: Every Child for Younger Patients With Cancer
  Recruiting · Children's Oncology Group · Birmingham, Alabama